HER2/Leptin Crosstalk in Breast Cancer
Abstract
Obesity in postmenopausal women is associated with increased breast cancer risk, development of more aggressive tumors and resistance to certain anti-breast cancer treatments. These effects might be mediated by obesity hormone leptin. Here we tested if leptin can transactivate the oncogenic receptor HER2. We found that HER2 and the leptin receptor (ObR) are coexpressed in several studied breast cancer cell lines. In MCF-7 cells, HER2 physically interacted with ObR and leptin treatment increased HER2 phosphorylation on Tyr 1248. Studies of 59 human breast cancers revealed that the presence of leptin correlated with ObR, and the whole leptin system was coexpressed with HER2 in ~50% of all tumors. Thus, coexpression of HER2 and the leptin/ObR system might contribute to enhanced HER2 activity and reduced sensitivity to anti- HER2 treatments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2008
- Accession Number
- ADA493685
Entities
People
- Eva Surmacz
Organizations
- Temple University